NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
Program Looks to Address Gaps in COVID-19 Data 04/14/2020
Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
AHRQ’s Registries User Guide Gets A New Edition 09/24/2020
Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020